Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $916.6 million.

  • Arrowhead Pharmaceuticals' Cash & Current Investments rose 6577.77% to $916.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $916.6 million, marking a year-over-year increase of 6577.77%. This contributed to the annual value of $919.4 million for FY2025, which is 3501.01% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Cash & Current Investments of $916.6 million as of Q4 2025, which was up 6577.77% from $919.4 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Cash & Current Investments' 5-year high stood at $1.1 billion during Q1 2025, with a 5-year trough of $165.3 million in Q4 2021.
  • Moreover, its 5-year median value for Cash & Current Investments was $466.7 million (2021), whereas its average is $529.3 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Cash & Current Investments skyrocketed by 20365.03% in 2022, and later crashed by 5609.93% in 2023.
  • Arrowhead Pharmaceuticals' Cash & Current Investments (Quarter) stood at $165.3 million in 2021, then soared by 203.65% to $501.8 million in 2022, then crashed by 56.1% to $220.3 million in 2023, then soared by 150.97% to $552.9 million in 2024, then surged by 65.78% to $916.6 million in 2025.
  • Its Cash & Current Investments was $916.6 million in Q4 2025, compared to $919.4 million in Q3 2025 and $900.4 million in Q2 2025.